Cancer最新文献

{"title":"POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort","authors":"Camilla Nero MD, PhD,&nbsp;Rita Trozzi MD,&nbsp;Federica Persiani MSc,&nbsp;Simone Rossi MSc,&nbsp;Luca Mastrantoni MD,&nbsp;Simona Duranti MD,&nbsp;Floriana Camarda MD,&nbsp;Ilenia Marino PharmD,&nbsp;Luciano Giacò PhD,&nbsp;Tina Pasciuto EngD, PhD,&nbsp;Maria De Bonis PhD,&nbsp;Martina Rinelli PhD,&nbsp;Emanuele Perrone MD,&nbsp;Flavia Giacomini PharmD,&nbsp;Domenica Lorusso MD, PhD,&nbsp;Alessia Piermattei MSc,&nbsp;Gianfranco Zannoni MD, PhD,&nbsp;Francesco Fanfani MD, PhD,&nbsp;Giovanni Scambia MD,&nbsp;Angelo Minucci PhD","doi":"10.1002/cncr.35731","DOIUrl":"10.1002/cncr.35731","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To date, 11 DNA polymerase epsilon (<i>POLE</i>) pathogenic variants have been declared “hotspot” mutations. Patients with endometrial cancer (EC) characterized by <i>POLE</i> hotspot mutations (<i>POLE</i>mut) have exceptional survival outcomes. Whereas international guidelines encourage deescalation of adjuvant treatment in early-stage <i>POLE</i>mut EC, data regarding safety in <i>POLE</i>mut patients with unfavorable characteristics are still under investigation. On the other hand, the spread of comprehensive genome profiling programs has underscored the need to interpret <i>POLE</i> variants not considered to be hotspots.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study provides a comprehensive analysis of 596 sequenced patients with EC. The genomic landscape of <i>POLE</i>mut EC was compared with cases harboring nonhotspot <i>POLE</i> mutations within the exonuclease domain. Additionally, the genomic characteristics of multiple classifiers, as well as those exhibiting unfavorable histopathological and clinical features, were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No significant genomic differences were observed among patients with <i>POLE</i>mut EC when comparing multiple classifiers to not-multiple classifiers or those with unfavorable clinical features. However, the tumor mutational burden differed in both comparisons, whereas the percentage of C&gt;G mutations only differed in the comparison based on clinical features. Specific <i>POLE</i> mutations, even if not considered to be hotspots, have genomic features comparable to <i>POLE</i>mut.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present findings confirm the absence of significant genomic differences among <i>POLE</i>mut patients regardless of multiple-classifier status or association with high-risk clinical features. Prognostic data will be essential to elucidate the clinical significance of <i>POLE</i> mutations not classified as hotspots that exhibit genomic characteristics similar to those in <i>POLE</i>mut patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer","authors":"Sarah M. Temkin MD","doi":"10.1002/cncr.35735","DOIUrl":"10.1002/cncr.35735","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!","authors":"Ahmet Emre Eşkazan MD","doi":"10.1002/cncr.35737","DOIUrl":"10.1002/cncr.35737","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers","authors":"Jibran Ahmed MD,&nbsp;Filip Janku MD, PhD,&nbsp;Daniel D. Karp MD,&nbsp;Sarina A. Piha-Paul MD,&nbsp;Apostolia M. Tsimberidou MD, PhD,&nbsp;Timothy Anthony Yap MD, PhD,&nbsp;Bettzy Stephen MBBS,&nbsp;Yali Yang PhD,&nbsp;Serdar Gurses PhD,&nbsp;Qian Liu PhD,&nbsp;Juhee Song PhD,&nbsp;Funda Meric-Bernstam MD,&nbsp;Aung Naing MD","doi":"10.1002/cncr.35728","DOIUrl":"10.1002/cncr.35728","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP8/9), has shown synergistic activity with immune checkpoint inhibitors in preclinical studies. This open label, phase 2 basket trial assessed the antitumor activity of combining talabostat and pembrolizumab (anti–programmed death-1 antibody) in advanced solid tumor patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The primary objective was assessment of dose-limiting toxicity (DLT) rates in the first six patients (lead-in stage) and response rate (efficacy stage; included cohort A [checkpoint inhibitor (ICI) naive] and cohort B [ICI pretreated]) for the study treatment using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST). Efficacy was assessed using a Bayesian optimal phase 2 design.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 31 patients enrolled in this trial (14 in cohort A, 17 in cohort B). The median age was 61 years; 17 (55%) patients were male and 21 (68%) patients were White. Among 19 (61%) patients evaluable for response, the best response was stable disease in nine patients, unconfirmed progressive disease in seven patients, and clinical progressive disease in three patients based on iRECIST. Disease control rate was 47%. One patient with programmed death-ligand 1 negative, microsatellite stable endometrial cancer had unconfirmed partial response. Median progression-free survival was 2.7 months; median overall survival was 20.5 months. One patient (cohort A) experienced a grade 4 hypotension as a DLT and treatment discontinuation. The most common toxicities were hypotension (22.6%), fatigue (9.7%), diarrhea, rash, thrombocytopenia, vomiting, syncope, general disorders and administration site conditions-other, and skin and subcutaneous tissue disorders-other, each in 6.5% of patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study of the combination of talabostat and pembrolizumab in patients with advanced solid tumors demonstrated predictable adverse events and limited activity. The combination was shown to be safe. Efficacy data shows immune stable disease in nine of 19 evaluable patients, and an unconfirmed immune partial response in a patient with endometrial cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression","authors":"Jordan Baeker Bispo PhD, MPH,&nbsp;Ahmedin Jemal DVM, PhD,&nbsp;Farhad Islami MD, PhD","doi":"10.1002/cncr.35724","DOIUrl":"10.1002/cncr.35724","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Low participation in cancer screening contributes to a disproportionate burden of cancer morbidity and mortality among adults with mental health (MH) disorders like depression and anxiety. It is unknown whether MH treatment affects screening participation in this population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the 2019 and 2021 National Health Interview Survey, data from screening-eligible respondents with a history of depression or anxiety were analyzed. Dependent variables include up-to-date screening for breast (BC), cervical (CVC), and colorectal cancer (CRC). Exposures of interest included past year receipt of any MH treatment and delayed or nonreceipt of counseling because of cost. Multivariable logistic regression was used to model associations between MH treatment and screening, controlling for sociodemographic and health care access characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The prevalence of up-to-date screening was lower for those who did not receive MH treatment than those who did among respondents reporting regular feelings of depression or anxiety (adjusted prevalence ratio [aPR] = 0.83; 95% CI, 0.76–0.91 for BC; aPR = 0.83; 95% CI, 0.77–0.88 for CVC; aPR = 0.78; 95% CI, 0.73–0.84 for CRC) or ever being diagnosed with depression or anxiety (aPR = 0.86; 95% CI, 0.81–0.91 for BC; aPR = 0.87; 95% CI, 0.83–0.91 for CVC; aPR = 0.84; 95% CI, 0.80–0.88 for CRC). BC screening was lower for those who reported delayed or nonreceipt of therapy because of cost than those who did not (aPR = 0.88; 95% CI, 0.78–0.99 among adults with regular feelings of depression or anxiety; aPR = 0.91; 95% CI, 0.83–0.99 among adults ever diagnosed).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MH treatment is associated with increased screening among adults with a history of depression or anxiety. Enhancing MH treatment receipt could reduce the cancer burden in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing socioeconomic barriers in the implementation of American Society of Clinical Oncology palliative care guidelines","authors":"Raffaele Giusti MD,&nbsp;Giampiero Porzio MD","doi":"10.1002/cncr.35730","DOIUrl":"10.1002/cncr.35730","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome","authors":"Neha Hippalgaonkar MD,&nbsp;Dezheng Huo PhD,&nbsp;Kent F. Hoskins MD","doi":"10.1002/cncr.35722","DOIUrl":"10.1002/cncr.35722","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of smoking status on engagement in remote symptom monitoring after oncologic surgery: Implications for symptom management and readmission rates","authors":"Jennifer R. Cracchiolo MD,&nbsp;Yuelin Li PhD,&nbsp;Michelle L. Lui MPH,&nbsp;Sigrid V. Carlsson MD, PhD, MPH,&nbsp;Richard S. Matulewicz MD,&nbsp;Jamie S. Ostroff PhD","doi":"10.1002/cncr.35708","DOIUrl":"10.1002/cncr.35708","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Remote symptom monitoring (RSM) is an evidence-based strategy shown to mitigate postoperative morbidity; however, platform engagement is required to benefit from RSM. Patients who report current smoking are at high risk for postoperative complications, but it is unknown whether smoking status influences engagement with RSM, symptom severity, or unanticipated acute care visits.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This observational case–control study was conducted in patients undergoing ambulatory oncologic surgery at a large cancer center. The authors examined the effect of current smoking status on adherence to an electronically delivered postoperative recovery-assessment tool. Symptom severity and readmissions by smoking status were also analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 19,481 patients who underwent surgery and were enrolled in RSM were included. The nonresponse rate (28%) in current smokers was significantly greater than the rate observed in never smokers (21%; odds ratio, 1.38; 95% confidence interval, 1.17–1.63; <i>p</i> &lt; .0001). Current smokers reported higher symptom scores for pain, wound swelling, constipation, and anxiety. The observed 30-day readmission rates were 3.6% for current smokers and 2.6% for never smokers, with overlapping confidence intervals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Current smokers report higher symptom burden after surgery yet are less likely to adopt proactive digital postoperative recovery strategies like RSM. Implementation strategies are needed to improve the engagement of current smokers in RSM if benefits are to be realized in this high-risk population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35688","DOIUrl":"10.1002/cncr.35688","url":null,"abstract":"&lt;p&gt;The addition of pembrolizumab to chemoradiotherapy for patients with high-risk locally advanced cervical cancer significantly improved overall survival (OS), according to the second interim analysis of the phase 3 KEYNOTE-A18 trial published in &lt;i&gt;The Lancet&lt;/i&gt;.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;The finding provides further support for adding pembrolizumab to chemoradiotherapy in this setting, and it builds on previously reported results showing a significant improvement in progression-free survival.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; These latter findings resulted in the US Food and Drug Administration’s approval of this regimen for patients with high-risk, International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Domenica Lorusso, MD, PhD, director of the Gynecological Oncology Unit at Humanitas Hospital San Pio X in Milan, Italy, and lead author of the study, first presented the results at the 2024 annual meeting of the European Society for Medical Oncology.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;At a median follow-up of 29.9 months, the 36-month OS rate was 82.6% for patients treated with pembrolizumab and chemoradiotherapy and 74.8% for patients treated with chemoradiotherapy alone, with a hazard ratio (HR) for death of 0.67 (95% CI, 0.50–0.90; &lt;i&gt;p&lt;/i&gt; = .004).&lt;/p&gt;&lt;p&gt;The trial included 1060 newly diagnosed patients with high-risk locally advanced cervical cancer randomized 1:1 to five cycles of pembrolizumab (200 mg) with concurrent chemoradiotherapy followed by 15 cycles of pembrolizumab (400 mg) (the investigational arm) or five cycles of a placebo with concurrent chemoradiotherapy followed by 15 cycles of a placebo (the control arm). Chemoradiotherapy included five cycles of cisplatin (40 mg/m&lt;sup&gt;2&lt;/sup&gt;) once weekly plus external-beam radiotherapy followed by brachytherapy.&lt;/p&gt;&lt;p&gt;At the time of randomization, patients were stratified by the planned type of external-beam radiotherapy (intensity-modulated radiotherapy [IMRT] or volumetric modulated arc therapy [VMAT] vs. non-IMRT or non-VMAT), the stage of cervical cancer at screening, and the planned total radiotherapy dose (&lt;70 vs. ≥70 Gy).&lt;/p&gt;&lt;p&gt;The benefit of adding pembrolizumab to chemoradiotherapy generally was consistent among prespecified subgroups. For example, the HR for death was 0.89 (95% CI, 0.55–1.44) for patients at FIGO stages IB2–IIB and 0.57 (95% CI, 0.39–0.83) for patients at FIGO stages III–IVA.&lt;/p&gt;&lt;p&gt;Grade 3 or higher treatment-related adverse events were seen in 78% and 70% of the patients in the investigational and placebo arms, respectively. The most common event was anemia, with decreases in both white blood cell counts and neutrophil counts. Potential immune-mediated adverse events occurred in 39% and 17% of the patients, respectively.&lt;/p&gt;&lt;p&gt;“In the context of modern and high-quality radiotherapy that is curative in 75% of patients, the addition of pembrolizumab further increases ","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35688","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential new treatment approach for intermediate-stage hepatocellular carcinoma","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35687","DOIUrl":"10.1002/cncr.35687","url":null,"abstract":"&lt;p&gt;The addition of lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) significantly improved progression-free survival (PFS) in comparison with TACE alone for patients with intermediate-stage hepatocellular carcinoma (HCC) according to interim results of the prospective, phase 3 LEAP-012 study.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;The lead author of the study, Josep M. Llovet, MD, PhD, director of the Liver Cancer Program and professor of medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, presented the results at the 2024 congress of the European Society for Medical Oncology in September.&lt;/p&gt;&lt;p&gt;At a median time of 25.6 months (from randomization to the data cutoff), the median PFS was 14.6 months for patients treated with the addition of lenvatinib and pembrolizumab to TACE and 10.0 months for patients treated with TACE alone, with a hazard ratio of 0.66 (95% CI, 0.51–0.84; &lt;i&gt;p&lt;/i&gt; = .0002).&lt;/p&gt;&lt;p&gt;The finding indicates that the prespecified significant improvement in the PFS endpoint of the study was met. No significant improvement in overall survival (OS) was found, but the data are considered immature at this interim analysis.&lt;/p&gt;&lt;p&gt;Grade 3–5 treatment-related adverse events occurred in 71.3% of patients treated with lenvatinib and pembrolizumab plus TACE and in 31.5% of patients treated with TACE alone, and they led to treatment discontinuation in 8.4% and 1.2% of patients, respectively.&lt;/p&gt;&lt;p&gt;Commenting on the study, Kenneth K. Tanabe, MD, professor of surgery at Harvard Medical School and chief of the Division of Oncologic and Gastrointestinal Surgery at Massachusetts General Hospital, says that the findings suggest that lenvatinib and pembrolizumab plus TACE could be a new treatment approach for HCC in the future, but it is “too early to say with any degree of certainty.”&lt;/p&gt;&lt;p&gt;He notes the significantly greater toxicity with the addition of lenvatinib and pembrolizumab to TACE and points to several unknowns that still need answers. First, he questions the benefit of adding pembrolizumab to this regimen considering prior data from the LEAP-002 study that showed no benefit from adding pembrolizumab to lenvatinib in comparison with lenvatinib alone for advanced HCC.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;Also left unanswered, he says, is whether giving TACE alone followed by lenvatinib (sequential administration) at the time of disease progression would yield equivalent OS to that achieved with TACE alone despite the inferior PFS.&lt;/p&gt;&lt;p&gt;“This is not practice changing at this time,” he says, but he urges oncologists to “stay tuned to this channel.”&lt;/p&gt;&lt;p&gt;The LEAP-012 trial included 480 patients with HCC randomized 1:1 to lenvatinib (12 mg for a body weight ≥60 kg and 8 mg for a body weight &lt;60 kg) and pembrolizumab (400 mg) or a placebo for up to 2 years. All patients in both groups received TACE, with the first administration occurring 2–4 weeks after the ","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35687","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}